PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention : A Pilot Study
Joint Authors
Schaefer, Katherine L.
Hosono, Kunihiro
Nakajima, Atsushi
Takahashi, Hirokazu
Endo, Hiroki
Maeda, Shin
Sugiyama, Michiko
Uchiyama, Takashi
Nakagama, Hitoshi
Sakai, Eiji
Source
Issue
Vol. 2010, Issue 2010 (31 Dec. 2010), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2010-08-02
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Natural & Life Sciences (Multidisciplinary)
Biology
Abstract EN
Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARγ), such as pioglitazone, are commonly used to treat persons with diabetes mellitus with improvement of insulin resistance.
Several reports have clearly demonstrated that PPARγ ligands could inhibit colorectal cancer cell growth and induce apoptosis.
Meanwhile, aberrant crypt foci (ACF) have come to be established as a biomarker of the risk of CRC in azoxymethane-treated mice and rats.
In humans, ACF can be detected using magnifying colonoscopy.
Previously, CRC and adenoma were used as a target for chemopreventive agents, but it needs a long time to evaluate, however, ACF can be a surrogate marker of CRC even for a brief period.
In this clinical study, we investigated the chemopreventive effect of pioglitazone on the development of human ACF as a surrogate marker of CRC.
Twenty-nine patients were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (15 mg/day) group, and ACF and adenoma were examined before and after 1-month treatment.
The number of ACF was significantly decreased (5.8±1.1 to 3.3±2.3) after 1 month of pioglitazone treatment, however, there was no significant change in the number of crypts/ACF or in the number and size of adenomas.
Pioglitazone may have a clinical application as a cancer-preventive drug.
This investigation is just a pilot study, therefore, further clinical studies are needed to show that the PPARγ ligand may be a promising candidate as a chemopreventive agent for colorectal carcinogenesis.
American Psychological Association (APA)
Takahashi, Hirokazu& Hosono, Kunihiro& Uchiyama, Takashi& Sugiyama, Michiko& Sakai, Eiji& Endo, Hiroki…[et al.]. 2010. PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention : A Pilot Study. PPAR Research،Vol. 2010, no. 2010, pp.1-4.
https://search.emarefa.net/detail/BIM-458006
Modern Language Association (MLA)
Takahashi, Hirokazu…[et al.]. PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention : A Pilot Study. PPAR Research No. 2010 (2010), pp.1-4.
https://search.emarefa.net/detail/BIM-458006
American Medical Association (AMA)
Takahashi, Hirokazu& Hosono, Kunihiro& Uchiyama, Takashi& Sugiyama, Michiko& Sakai, Eiji& Endo, Hiroki…[et al.]. PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention : A Pilot Study. PPAR Research. 2010. Vol. 2010, no. 2010, pp.1-4.
https://search.emarefa.net/detail/BIM-458006
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-458006